NO960545D0 - Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin - Google Patents

Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin

Info

Publication number
NO960545D0
NO960545D0 NO960545A NO960545A NO960545D0 NO 960545 D0 NO960545 D0 NO 960545D0 NO 960545 A NO960545 A NO 960545A NO 960545 A NO960545 A NO 960545A NO 960545 D0 NO960545 D0 NO 960545D0
Authority
NO
Norway
Prior art keywords
administration
treatment
adverse effects
effects associated
extracellular hemoglobin
Prior art date
Application number
NO960545A
Other languages
English (en)
Other versions
NO960545L (no
Inventor
Michael J Gerber
Original Assignee
Somatogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somatogen Inc filed Critical Somatogen Inc
Publication of NO960545D0 publication Critical patent/NO960545D0/no
Publication of NO960545L publication Critical patent/NO960545L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO960545A 1993-08-13 1996-02-12 Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin NO960545L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10613893A 1993-08-13 1993-08-13
PCT/IB1994/000239 WO1995005167A2 (en) 1993-08-13 1994-08-09 Treatment of adverse effects associated with administration of extracellular hemoglobin

Publications (2)

Publication Number Publication Date
NO960545D0 true NO960545D0 (no) 1996-02-12
NO960545L NO960545L (no) 1996-02-29

Family

ID=22309699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960545A NO960545L (no) 1993-08-13 1996-02-12 Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin

Country Status (8)

Country Link
US (1) US5750132A (no)
EP (2) EP0784983A3 (no)
JP (1) JPH09501441A (no)
AU (2) AU7194694A (no)
CA (1) CA2167716A1 (no)
IS (1) IS4198A (no)
NO (1) NO960545L (no)
WO (1) WO1995005167A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026195A1 (en) * 1994-03-28 1995-10-05 Baxter International Inc. Therapeutic use of hemoglobin in the treatment of blood vessel blockage
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
FR2809624B1 (fr) * 2000-05-31 2002-08-02 Centre Nat Rech Scient Utilisation comme substitut sanguin d'une hemoglobine extracellulaire de poids moleculaire eleve
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) * 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
EP2427483B1 (en) * 2009-05-07 2015-03-11 Hemarina Novel heamoglobin and uses thereof
WO2013036383A1 (en) * 2011-09-06 2013-03-14 Bing Lou Wong Oral delivery for hemoglobin based oxygen carriers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4965065A (en) * 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
US5043358A (en) * 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
EP0561245A1 (en) * 1987-05-16 1993-09-22 Somatogenetics International, Inc. Blood substitutes comprising recombinant hemoglobin
NL8901174A (nl) * 1989-05-10 1990-12-03 Het Hoofd Van De Afdeling Mili Hemoglobine-preparaat en gebruik daarvan.
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2080589A1 (en) * 1990-04-16 1991-10-17 Joseph De Angelo Expression of recombinant hemoglobin in yeast
DE69132763D1 (de) * 1990-12-20 2001-11-15 Univ Alabama Res Foundation Bi Transgenes, vernetztes hämoglobin
AU2140492A (en) * 1991-05-14 1992-12-30 Biopure Corporation Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5295944A (en) * 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10

Also Published As

Publication number Publication date
EP0717619A1 (en) 1996-06-26
EP0784983A3 (en) 2001-03-21
WO1995005167A2 (en) 1995-02-23
WO1995005167A3 (en) 1995-04-13
AU7194694A (en) 1995-03-14
IS4198A (is) 1995-02-14
AU7011098A (en) 1998-07-30
NO960545L (no) 1996-02-29
US5750132A (en) 1998-05-12
EP0784983A2 (en) 1997-07-23
CA2167716A1 (en) 1995-02-23
JPH09501441A (ja) 1997-02-10

Similar Documents

Publication Publication Date Title
LV10878A (lv) Adas apstradasana ar izveletiem amfifiliem kopolimeriem
NO912672L (no) Fremgangsmaate for fremstilling av terapeutisk aktive oligomerer.
NO934304L (no) Fremgangsmaate for behandling av fluoralumosilikatglass
NO910828D0 (no) Preparat for behandling av erektil funksjonssvikt.
MX9205981A (es) Administracion transdermica de melatonina.
IT1236831B (it) Apparecchio per il trattamento dell'intestino in particolare per enteroclisma
BR9406209A (pt) Derivados heterociclicos no tratamento de isquemia e doenças relacionadas
NO960173L (no) Tri-substituerte imidazoler med multipel-terapeutiske egenskaper
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
ZA872624B (en) Medicament for the treatment of inflammations of the eye
NO914667D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylderivater
EP0458641A3 (en) Use of prostaglandin derivatives in the treatment of congestive heart failure
DE69309698D1 (de) Hautbehandlung mit adhäsionsverstärkenden eigenschaften
DE69319639D1 (de) Pulsmesser
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
NO922521D0 (no) Piperidinyletanolderivater med terapeutisk virkning
DE69122929D1 (de) Pulsmessgerät
NO914071D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
KR930702990A (ko) 섬유성 질병 치료제로서의 프로스타사이클린- 및 카르바사이클린 유도체
IT1252659B (it) Procedimento per la depurazione dell'1,1,1-trifluoro-2-fluoroetano e dell'1,1,1-trifluoro-2,2-dicloroetano
GB9222012D0 (en) Improvements relating to the treatment of haemophilia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application